Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impentri in Critical COVID-19 ARDS
NCT04953052Phase 2Withdrawn
- Sponsor
- Exvastat Ltd
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib + durvalumab in acute respiratory distress syndrome (ARDS), sponsored by Exvastat Ltd. Planned start Oct 2021; status: withdrawn.
02
Drugs
olaparib + durvalumab
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04953052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953052.